6.22

1.97% 0.12

Nuvation Bio Inc (NUVB)

Overview News Price History Option Chain Discussions Forecast

Nuvation Bio Inc stock is traded at $6.22, with a volume of 13.33M. It is up +1.97% in the last 24 hours and up +5.42% over the past month. Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Previous Close:

$6.10

Open:

$6.02

24h Volume:

13.33M

Relative Volume:

2.07

Market Cap:

$2.18B

Revenue:

$143.05M

Net Income/Loss:

$-145.99M

P/E Ratio:

-14.53

EPS:

-0.4282

Net Cash Flow:

$-134.06M

1W Performance:

-5.76%

1M Performance:

+5.42%

6M Performance:

+7.80%

1Y Performance:

+125.36%

1-Day Range:

$5.88

$6.28

1-Week Range:

$5.88

$6.62

52-Week Range:

$2.57

$9.75

Nuvation Bio Inc Stock (NUVB) Company Profile

Name

Nuvation Bio Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

332-208-6102

Address

1500 BROADWAY, NEW YORK

Employee

307

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

NUVB's Discussions on Twitter

Compare NUVB vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NUVB Nuvation Bio Inc	6.22	2.25B	143.05M	-145.99M	-134.06M	-0.4282
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-24-25	Initiated	Truist	Buy
Nov-19-25	Initiated	B. Riley Securities	Buy
Sep-30-25	Initiated	Jefferies	Buy
Apr-23-25	Initiated	Citizens JMP	Mkt Outperform
Mar-27-24	Upgrade	Jefferies	Hold → Buy
Mar-26-24	Upgrade	BTIG Research	Neutral → Buy
Jan-06-23	Downgrade	Jefferies	Buy → Hold
Aug-02-22	Downgrade	BMO Capital Markets	Outperform → Market Perform
Aug-02-22	Downgrade	BTIG Research	Buy → Neutral
May-04-22	Initiated	H.C. Wainwright	Buy
Oct-15-21	Resumed	BTIG Research	Buy
Apr-06-21	Initiated	RBC Capital Mkts	Outperform
Mar-08-21	Initiated	BMO Capital Markets	Outperform
Mar-08-21	Initiated	BTIG Research	Buy
Mar-08-21	Initiated	Cowen	Outperform
Mar-08-21	Initiated	Jefferies	Buy
Mar-08-21	Initiated	Wedbush	Outperform

View All

Nuvation Bio Inc Stock (NUVB) Latest News

Aug 13, 2026

Nuvation Bio (NUVB) Q2 2026 Earnings Call Transcript - The Globe and Mail

Aug 13, 2026

Aug 11, 2026

Brokers Set Expectations for Nuvation Bio FY2026 Earnings - MarketBeat

Aug 11, 2026

Nuvation Bio Inc. (NYSE:NUVB) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Aug 11, 2026

559,180 Shares in Nuvation Bio Inc. $NUVB Bought by Renaissance Technologies LLC - MarketBeat

Aug 11, 2026

Aug 10, 2026

Power Solutions International And 2 More Growth Stocks With Strong Insider Ownership - simplywall.st

Aug 10, 2026

HC Wainwright Predicts Nuvation Bio Q1 Earnings - MarketBeat

Aug 10, 2026

Aug 08, 2026

Nuvation Bio Q2 Earnings Call Highlights - MarketBeat

Aug 08, 2026

Aug 07, 2026